ResMed is a global pioneer and leader in respiratory care. With our programme to research clinical areas related to sleep-disordered breathing, we aim to further develop our in-depth knowledge on sleep and respiratory disorders. That’s why we support and actively engage in research initiatives related to cardiology.
Explore our research initiatives for cardiology below.
SERVE-HF is a multinational, multicentre, randomised and parallel trial designed to assess the effects of adaptive servo ventilation (ASV) on morbidity and mortality in patients with predominant Central Sleep Apnoea (CSA) and heart failure (HF).
Initiated at the beginning of 2008, SERVE-HF is underway in more than 80 centres throughout Europe and Australia. Enrolment was completed in May 2013, with 1325 randomised patients to be followed for a minimum of 2 years. The study is expected to end in mid-2015.
For more information on SERVE-HF, visit our dedicated website.
SCHLA-HF is a major multi-centre screening registry exploring the prevalence and prediction of sleep-disordered breathing and heart failure. It is the largest database of its kind, with 10,000 patients enrolled in 213 cardiology centres.
CAT HF is a multi-centre, randomised and controlled trial aiming to assess the effects of ASV in patients after a hospitalisation for acute decompensated heart failure. It began in multiple US sites in September 2013. Results are expected in 2016.
The FACE study is a French prospective, multicentre, observational cohort that will provide long-term data on morbidity and mortality of heart failure patients using ASV. So far over 270 patients have been enrolled by 30 centres, with a target of 300 chronic HF patients at the end of December 2014.
For clinical literature on sleep apnoea and cardiology, consult our dedicated ResMed page